Gastrointestinal Cancer – Page 4 – Medical News Asia

EBV, MSI, and CPS predict pembrolizumab outcome in gastric cancer

16 July 2018/0 Comments/in Gastrointestinal Cancer, Oncology, Immunotherapy, Translational Research/by scienterrific

Metastatic gastric cancer (mGC) patients with microsatellite instability-high (MSI-H) or Epstein-Barr virus (EBV)-positive tumours, or those with a positive (≥1%) combined positive score (CPS) respond best to pembrolizumab PD-1 immunotherapy.

Ipilimumab plus nivolumab FDA approved for MSI-H and dMMR pre-treated mCRC

11 July 2018/2 Comments/in Gastrointestinal Cancer, US FDA Onc\Haem Approvals, Oncology, Immunotherapy/by scienterrific

On July 10th, the FDA granted accelerated approval to ipilimumab (Yervoy©, Bristol-Myers Squibb) for use in combination with nivolumab (Opdivo©) for the treatment of adult and paediatric patients ≥12 years of age with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

Combination encorafenib plus binimetinib for unresectable/metastatic BRAF V600E or V600K-positive melanoma FDA approved

2 July 2018/0 Comments/in Gastrointestinal Cancer, US FDA Onc\Haem Approvals, Oncology, Targeted Therapies/by scienterrific

On June 27th, the FDA approved Array Biomarpharma’s combination encorafenib (BRAFTOVI®) plus binimetinib (and MEKTOVI®) for patients with unresectable or metastatic melanoma harbouring a BRAF V600E or V600K mutation detected by an FDA-approved test.

ASCO 2018 HCC: The ASCO18 hepatocellular cancer track summarised

10 June 2018/5 Comments/in ASCO 2018 Annual Meeting, Gastrointestinal Cancer, Conferences, Oncology, Chemotherapy, Immunotherapy, Targeted Therapies, Translational Research/by Anne John Michael

This year’s American Society of Clinical Oncology (ASCO) annual meeting includes two Phase III studies in the second-line treatment of the disease. Moreover, data with several immune-checkpoint inhibitors were presented, including the KEYNOTE-224 with pembrolizumab. Welcome to the summary of the ASCO 2018 HCC track.

Death due to cancer on the decline for most tumours in Europe

31 March 2018/0 Comments/in Gastrointestinal Cancer, Oncology, Endocrine Therapy/by Stijn van den Borne, MSc

Do you know your lifetime risk on Pancreatic Cancer?

20 November 2017/0 Comments/in Gastrointestinal Cancer, Oncology/by Stijn van den Borne, MSc

November turns purple for pancreatic cancer awareness. Focus is on one of the most difficult-to-treat tumours with the final objective: to double the survival of pancreatic cancer by 2020. What is your risk to develop pancreatic cancer? And how likely are you to get cured of the disease?

Pembrolizumab approved for advanced gastric cancer

22 September 2017/0 Comments/in Gastrointestinal Cancer, US FDA Onc\Haem Approvals, Chemotherapy, Immunotherapy, Translational Research/by Stijn van den Borne, MSc

On September 22, 2017, the FDA granted accelerated approval to pembrolizumab (KEYTRUDA, Merck) for use in patients with locally advanced or metastatic, gastric or gastroesophageal junction (GEJ) adenocarcinoma positive for PD-L1 as determined by an FDA-approved companion diagnostic (CDx) and progressing after ≥2 prior systemic therapies, including a fluoropyrimidine- and platinum-containing regimen, and, when appropriate, HER2-targeted therapy.

Nivolumab approved for sorafenib-refractory HCC

22 September 2017/in Gastrointestinal Cancer, US FDA Onc\Haem Approvals, Immunotherapy, Targeted Therapies/by Stijn van den Borne, MSc

On September 22, 2017, the Food and Drug Administration granted accelerated approval to nivolumab (OPDIVO, Bristol-Myers Squibb Co.) for the treatment of hepatocellular carcinoma (HCC) in patients who have been previously treated with sorafenib. Approval was based on a 154-patient subgroup of CHECKMATE-040 (NCT 01658878), a multicenter, open-label trial conducted in patients with HCC and […]